What is it about?
The aim of the study was to investigate the prognostic value of circulating Bcl-2 and anti-p53 antibodies (p53Abs) in a 17.5-year follow-up of breast cancer patients.
Featured Image
Photo by Kalen Emsley on Unsplash
Why is it important?
Our results suggest that breast cancer patients with high serum levels of p53Abs and Bcl-2 present an especially unfavorable group in a long follow-up.
Perspectives
Analysis of these circulating, apoptosis related markers, may be useful in defining the group of patients that may benefit of some therapeutic modalities.
Maja Sirotkovic-Skerlev
School of Medicine, University of Zagreb, Croatia
Read the Original
This page is a summary of: Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years), Cancer Biomarkers, February 2021, IOS Press,
DOI: 10.3233/cbm-201497.
You can read the full text:
Contributors
The following have contributed to this page
